PMID- 32790904
OWN - NLM
STAT- MEDLINE
DCOM- 20210420
LR  - 20210420
IS  - 1601-0825 (Electronic)
IS  - 1354-523X (Linking)
VI  - 27
IP  - 4
DP  - 2021 May
TI  - Vortioxetine versus other antidepressants in the treatment of burning mouth 
      syndrome: An open-label randomized trial.
PG  - 1022-1041
LID - 10.1111/odi.13602 [doi]
AB  - OBJECTIVES: This randomized open-label trial compared the efficacy and 
      tolerability of vortioxetine (15 mg/daily) with different antidepressants in the 
      treatment of patients with burning mouth syndrome (BMS). METHODS: One and hundred 
      fifty BMS patients were randomized into five groups and treated with either 
      vortioxetine, paroxetine (20 mg/daily), sertraline (50 mg/daily), escitalopram 
      (10 mg/daily) or duloxetine (60 mg/daily). The Visual Analogue Scale (VAS), Total 
      Pain Rating Index (T-PRI), Hamilton Rating Scales for Depression (HAM-D) and 
      Anxiety (HAM-A), and Clinical Global Impression Improvement (CGI-I) and Efficacy 
      scales (CGI-E) were performed at baseline and after 2, 4, 6, and 12 months of 
      treatment. Any adverse events (AEs) were tabulated for each group. Descriptive 
      statistics, including the Kruskal-Wallis non-parametric test and the Friedman 
      non-parametric test for median comparisons between different times, were used. 
      RESULTS: All the antidepressants (AD) were associated with a significant decrease 
      in the VAS, T-PRI, HAM-A, HAM-D, CGI-I, and CGI-E scores in the long-term 
      (p < .001). However, the response rate of the vortioxetine group showed a 
      significant reduction after six months. The medians, after 6 months, were as 
      follows: VAS 0.0; T-PRI 2.0; HAM-A 7.0; HAM-D 7.0; CGI-I 1.0; and CGI-E 1.0 with 
      a lower incidence of AEs (p < .019). CONCLUSION: Vortioxetine was efficacious 
      with a shorter latency of action and fewer AEs compared with other ADs.
CI  - (c) 2020 John Wiley & Sons A/S . Published by John Wiley & Sons Ltd. All rights 
      reserved.
FAU - Adamo, Daniela
AU  - Adamo D
AUID- ORCID: 0000-0002-3784-4229
AD  - Department of Neurosciences, Reproductive and Odontostomatological Sciences, 
      University Federico II of Naples, Naples, Italy.
FAU - Pecoraro, Giuseppe
AU  - Pecoraro G
AD  - Department of Neurosciences, Reproductive and Odontostomatological Sciences, 
      University Federico II of Naples, Naples, Italy.
FAU - Coppola, Noemi
AU  - Coppola N
AD  - Department of Neurosciences, Reproductive and Odontostomatological Sciences, 
      University Federico II of Naples, Naples, Italy.
FAU - Calabria, Elena
AU  - Calabria E
AD  - Department of Neurosciences, Reproductive and Odontostomatological Sciences, 
      University Federico II of Naples, Naples, Italy.
FAU - Aria, Massimo
AU  - Aria M
AD  - Department of Economics and Statistics, University Federico II of Naples, Naples, 
      Italy.
FAU - Mignogna, Michele
AU  - Mignogna M
AD  - Department of Neurosciences, Reproductive and Odontostomatological Sciences, 
      University Federico II of Naples, Naples, Italy.
LA  - eng
GR  - Department of Neurosciences, Reproductive and Odontostomatological Sciences, Oral 
      Medicine Unit, of the "Federico II University of Naples", Italy./
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20200915
PL  - Denmark
TA  - Oral Dis
JT  - Oral diseases
JID - 9508565
RN  - 0 (Antidepressive Agents)
RN  - 3O2K1S3WQV (Vortioxetine)
MH  - Antidepressive Agents/adverse effects
MH  - *Burning Mouth Syndrome/drug therapy
MH  - *Depressive Disorder, Major/drug therapy
MH  - Double-Blind Method
MH  - Humans
MH  - Treatment Outcome
MH  - Vortioxetine/therapeutic use
OTO - NOTNLM
OT  - anxiety
OT  - depression
OT  - oral pain
OT  - side effects
OT  - sleep disturbance
OT  - vortioxetine
EDAT- 2020/08/14 06:00
MHDA- 2021/04/21 06:00
CRDT- 2020/08/14 06:00
PHST- 2020/07/31 00:00 [revised]
PHST- 2020/05/29 00:00 [received]
PHST- 2020/08/04 00:00 [accepted]
PHST- 2020/08/14 06:00 [pubmed]
PHST- 2021/04/21 06:00 [medline]
PHST- 2020/08/14 06:00 [entrez]
AID - 10.1111/odi.13602 [doi]
PST - ppublish
SO  - Oral Dis. 2021 May;27(4):1022-1041. doi: 10.1111/odi.13602. Epub 2020 Sep 15.